Company Overview
Snapshot
Founded in July 2019 by Yaacov Nitzan, AquaPass operates with 11–50 employees. The company has completed 2 funding rounds, attracting 2 investors. In January 2022, AquaPass secured a Seed round from Arbelon Holdings Ltd.
Business overview
AquaPass is an early-stage medical device startup focused on transforming the treatment of fluid overload. The company has developed an award-winning, patented, noninvasive, and drug-free system that removes excess fluids directly from the interstitial compartment through the skin by enhancing natural perspiration. This system consists of a wearable body suit with a microclimate generator designed to optimize environmental conditions for inducing perspiration and immediate evaporation, ensuring patient comfort. The AquaPass system serves the healthcare industry, specifically targeting patients and providers in the medical treatment and therapeutics sector, offering efficient and safe treatment options for use in hospitals, outpatient clinics, and home settings.
Strategic signal
In October 2022, AquaPass's innovative sweat suit technology, designed to naturally remove excess fluids from the body, was undergoing testing at Rambam Hospital. Initial findings from this ongoing study indicated a significant 30-50% decrease in stress hormone levels in heart failure patients. This development signals a potential paradigm shift in fluid overload treatment, offering a non-pharmacological alternative that could reduce reliance on medications with long-term kidney side effects, thereby validating AquaPass's technology as a promising solution for improving patient outcomes and reducing hospitalization rates.
Log in to access full profile ›Company Intelligence Q&A
- What is AquaPass's core technology for fluid overload treatment?
- AquaPass has developed an award-winning, patented, noninvasive, and drug-free fluid overload treatment system. This system removes fluids directly from the interstitial compartment through the skin by controlling and enhancing the natural process of perspiration, using a wearable body suit with a microclimate generator.
- When was AquaPass founded and by whom?
- AquaPass was founded in July 2019 by Yaacov Nitzan, who serves as the Founder & CTO.
- What significant clinical development occurred for AquaPass in October 2022?
- In October 2022, AquaPass's technology was being tested at Rambam Hospital for heart failure patients. Initial findings from the ongoing study indicated a 30-50% decrease in stress hormone levels, demonstrating the system's effectiveness in naturally removing excess fluids.
- Which investors participated in AquaPass's funding rounds?
- AquaPass has secured funding from investors including Arbelon Holdings Ltd in January 2022 and BRM Group in July 2019.
- What are the potential benefits of the AquaPass system for patients?
- The AquaPass system aims to reduce the need for medication that can have harmful long-term effects on the kidneys by providing a noninvasive, drug-free treatment. It also maintains a stable core temperature, ensures patient comfort, and can be optimized for individual physiology, offering treatment flexibility across hospital, outpatient, and home settings.